Evidence map›Paper›PMID 37961609›Full record

ArticleResearch square2023

Cytokine polarized, alternatively activated bone marrow neutrophils drive axon regeneration.

Andrew D Jerome, Andrew R Sas, Yan Wang, Jing Wen, Jeffrey R Atkinson, Amy Webb, Tom Liu, Benjamin M Segal

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrew D JeromeDepartment of Neurology, The Ohio State University.
Andrew R SasDepartment of Neurology, The Ohio State University.
Yan WangDepartment of Neurology, The Ohio State University.
Jing WenThe James Comprehensive Cancer Center, The Ohio State University.
Jeffrey R AtkinsonDepartment of Neurology, The Ohio State University.
Amy WebbThe James Comprehensive Cancer Center, The Ohio State University.
Tom LiuDepartment of Neurology, The Ohio State University.
Benjamin M SegalDepartment of Neurology, The Ohio State University.ORCID https://orcid.org/0000-0002-0906-6319
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Immune mediated regeneration of retinal ganglion cell axons following optic nerve traumaR01EY028350 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEGAL, BENJAMIN M · 2017 to 2020
$1.5M
A novel inflammatory cell with neuroprotective and neuroregenerative propertiesR01EY029159 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEGAL, BENJAMIN M · 2018 to 2022
$1.4M
Neutrophil driven recovery from traumatic and ischemic optic neuropathyK08EY029362 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAS, ANDREW ROBERT · 2018 to 2022
$898k
NEI NIH HHS K08 EY029362NEI NIH HHS L40 EY029522NEI NIH HHS R01 EY028350NEI NIH HHS R01 EY029159
6 · The paper itself

Abstract

The adult central nervous system (CNS) possesses a limited capacity for self-repair. Severed CNS axons typically fail to regrow. There is an unmet need for treatments designed to enhance neuronal viability, facilitate axon regeneration, and ultimately restore lost neurological functions to individuals affected by traumatic CNS injury, multiple sclerosis, stroke, and other neurological disorders. Here we demonstrate that both mouse and human bone marrow (BM) neutrophils, when polarized with a combination of recombinant interleukin (IL)-4 and granulocyte-colony stimulating factor (G-CSF), upregulate alternative activation markers and produce an array of growth factors, thereby gaining the capacity to promote neurite outgrowth. Moreover, adoptive transfer of IL-4/G-CSF polarized BM neutrophils into experimental models of CNS injury triggered substantial axon regeneration within the optic nerve and spinal cord. These findings have far-reaching implications for the future development of autologous myeloid cell-based therapies that may bring us closer to effective solutions for reversing CNS damage.

Identifiers

PMID37961609
PMCPMC10635390
OpenAlexW4388070403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.